Clinical Trial Update: Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating intravenous ABT-874 versus placebo in active Crohn's disease; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ABT-874 (briakinumab)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED